Advertisement

Nizatidin pp 83-92 | Cite as

Literatur

  • Rudolf Arnold
  • Hanns-Gerd Dammann
  • Peter Minartz
  • Hans-Dieter Peters
  • Bernd Simon
Chapter
  • 11 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anonymus (1984) Nizatidine. Drug Fut 9(9): 655Google Scholar
  2. Anonymus (1985) Nizatidine Axid. Drug Fut 9(9): 787Google Scholar
  3. Anonymus (1986) Nizatidine Axid. Drug Fut 11(9): 807Google Scholar
  4. Anonymus (1987) Nizatidine Axid. Drug Fut 12(9): 913Google Scholar
  5. Anonymus (1988) Nizatidine. Drug Fut 13(9): 897Google Scholar
  6. Aronoff G, Sloan R, Bopp R, Walters J, Bergstrom R, Callaghan J (1986) Nizatidine Kinetics in Patients with Renal Insufficiency. Clin Pharmacol Ther 39:178Google Scholar
  7. Aronoff G (1986a) Nizatidine in Subjects with or without Chronic Renal Failure. Lilly Research Labs. — Clinical Dokumentation Protocol 28 (unveröffentlichte Daten)Google Scholar
  8. Arthur BH (1981) The Acute Oral Toxicity of Compound LY139037 in the Mouse. Lilly Research Labs. — Toxicology Report Nr. 1 (unveröffentlichte Daten)Google Scholar
  9. Arthur BH (1981 a) The Acute Oral Toxicity of Nizatidine in the Fischer 344 Rat. Lilly Research Labs. — Toxicology Report Nr.2 (unveröffentlichte Daten)Google Scholar
  10. Arthur BH (1981b) The Acute Intraveneous Toxicity of Nizatidine in the Mouse. Lilly Research Labs. — Toxicology Report Nr.3 (unveröffentlichte Daten)Google Scholar
  11. Arthur BH (1981 c) The Acute Intraveneous Toxicity of Nizatidine in the Rat. Lilly Research Labs. — Toxicology Report Nr.4 (unveröffentlichte Daten)Google Scholar
  12. Arvela P, Pasanen P, Pelkanen O (1986) Effect of Induction on the Inhibitor of Drug Metabolism by Histamine H2-Receptor Antagonists. Naunyn Schmiedebergs Arch Pharmacol 332 (Suppl): 38Google Scholar
  13. Axon ATR (1986) Potential Hazards of Hypochlorhydria in the Treatment of Peptic Ulcer. Scand J Gastroenterol 21 (Suppl 122): 17Google Scholar
  14. Bergstrom RE (1987) The Clinical Pharmacology of Nizatidine. European Nizatidine Symposium, BrusselsGoogle Scholar
  15. Bergstrom RE, Golichowski A, Obermeyer BD (1987 a) Breast milk Study. Lilly Research Labs. — IND Protocol Nr. B5Q-LC-NABE (unveröffentlichte Daten)Google Scholar
  16. Betton GR, Salmon GK (1984) Pathology of the Forestomach in Rats Treated for One Year with a New Histamine H2-Receptor Antagonist, SK 93479 Trihy-drochloride. Scand J Gastroenterol 19 (Suppl 101): 103Google Scholar
  17. Bewsey BJ (1983) The Effect of Nizatidine on the Induction of Forward Mutation at the Thymidine Kinase Locus of L5178Y Mouse Lymphoma Cells. Lilly Research Labs. — Toxicology Report Nr.27 (unveröffentlichte Daten)Google Scholar
  18. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM (1972) Definition and Antagonism of Histamine H2-Receptors. Nature 236: 385PubMedGoogle Scholar
  19. Bovero E, Poletti M, Boero A et al. (1987) Nizatidine in the Short-Term Treatment of Duodenal Ulcer — An Italian Multicenter Study. Hepatogastroenterology 34: 269PubMedGoogle Scholar
  20. Bridge TL, Newman KS (1981) A 14-Day Acute Toxicity Study of Nizatidine (LY139037) Administered by Nasogastric Gavage to Rhesus Monkeys. Lilly Research Labs. — Toxicology Report Nr.26 (unveröffentlichte Daten)Google Scholar
  21. Brittain RT, Jack D, Price BJ (1981) Recent Developments in Histamin H2-Antagonists. Trends Pharmacol Sei 2: 310Google Scholar
  22. Broden R, Canuine A, Heel R (1982) Ranitidine: A Review of its Pharmacology and Therapeutic Use in Peptic Ulcer Disease and Other Allied Diseases. Drugs 24: 267Google Scholar
  23. Byrd RA (1984) A Teratology Study of Nizatidine Administered Orally to Wistar Rats. Lilly Research Labs. — Toxikology Report Nr.29 (unveröffentlichte Daten)Google Scholar
  24. Callaghan J (1983) Oral Administration of Nizatidine to Normal Male Volunteers l.Dose Ranging Study. Lilly Research Labs. — Clinical Dokumentation Protocol 3 (unveröffentlichte Daten)Google Scholar
  25. Callaghan J (1983 a) Multiple Dose Safety Study an Gastric Acid Suppression of Oral LY139037. Lilly Research Labs. — Clinical Dokumentation Protocol 4 (Unveröffentlichte Daten)Google Scholar
  26. Callaghan J, Bergstrom R, Obermeyer B, King E, Offen W (1985) Intravenous Nizatidine Kinetics and Acid Suppression. Clin Pharmacol Ther 37(2): 162PubMedGoogle Scholar
  27. Callaghan J, Bergstrom R, Knadler M, Rubin A (1986) Nizatidine Disposition in Elderly Subjects. Clin Pharmacol Ther 39(2): 185Google Scholar
  28. Callaghan J (1986 a) The Interactions of H2-Blockers with Lidocaine and Indocyanine Green. Lilly Research Labs. — Clinical Dokumentation Protocol 27 (unveröffentlichte Daten)Google Scholar
  29. Callaghan J (1986 b) The Disposition of 14C-Nizatidine in Man. Lilly Research Labs. — Clinical Dokumentation Protocol 22 (unveröffentlichte Daten)Google Scholar
  30. Callaghan J, Bergstrom R, Rubin A et al. (1987) A Pharmacokinetic Profile of Nizatidine in Man. Scand J Gastroenterol 22 (Suppl 136): 9Google Scholar
  31. Callaghan J, Rubin A, Knadler M, Bergstrom R (1987 a) Nizatidine, an H2Receptor Antagonist: Disposition and Safety in the Elderly. J Clin Pharmacol 27(8): 618PubMedGoogle Scholar
  32. Callaghan J (1987b) Nizatidine: Effects on Aspirin-induced Gastrointestinal Red Blood Cell Loss. Gastroenterology 92(5): 1336Google Scholar
  33. Callaghan J (1987c) Nizatidine: Effects on Aspirin-induced Gastrointestinal Red Blood Cell Loss. Pharmacologist 23(3): 590Google Scholar
  34. Cerulli M, Cloud M, Offen W, Chernish S, Matsumoto C (1987) Nizatidine as Maintenance Therapy of Duodenal Ulcer Disease in Remission. Scand J Gastroenterol 22 (Suppl 136): 79Google Scholar
  35. Cloud M, Matsumoto C, Offen W (1986) Two Nighttime Doses of Nizatidine Compared with Placebo in the Treatment of Acute Duodenal Ulcer. Am J Gastroenterol 81(9): 867Google Scholar
  36. Cloud M, Offen W, Matsumoto C (1986 a) Nizatidine Compared with Placebo in the Prevention of Recurrent Duodenal Ulcer. Am J Gastroenterol 81(9): 866Google Scholar
  37. Cloud M, Matsumoto C, Offen W (1986 b) Three Doses of Nizatidine Compared with Placebo in Treatment of Acute Duodenal Ulcer. Dig Dis Sei 31 (10 Suppl): 161Google Scholar
  38. Cloud M (1987) Safety of Nizatidine in Clinical Trials Conducted in the USA and Europe. Scand J Gastroenterol 22 (Suppl 136): 29Google Scholar
  39. Cloud M (1987 a) Prevention of Recurrent Duodenal Ulcer Disease with Nizati-dine. Gastroenterology 92(5): 1348Google Scholar
  40. Cloud M (1987 b) Efficacy and safety of Nizatidine 150 mg twice daily in the treatment of duodenal ulcer disease. Gastroenterology 92 (5, Part 2): 1348Google Scholar
  41. Cunningham M, Male P-J, Griessen M, Striberni R, Loizeau E (1985) 24-Hour-H+-Activity, Nocturnal Acid and Pepsin Output on A New H2-Receptor Antagonist Nizatidine. Am J Gastroenterol 80(10): 839Google Scholar
  42. Dammann HG, Müller P, Simon B (1983) 24 Hour Intragastric Acidity and Single Nighttime Dose of Three H2-Blockers. Lancet 2:1078PubMedGoogle Scholar
  43. Damman HG, Jacubasch T, Walter T, Müller P, Simon B (1984) Intragastrale 24-Stunden-H+-Aktivität unter H2-Rezeptor-Antagonisten. Therapiewoche 34/36: 5092Google Scholar
  44. Dammann HG, Gottlieb W, Walter T, Müller P, Simon B (1985) Nocturnal Administration of Five Histamine H2-Receptor Antagonists: A Single Blind Comparative Study. Gastroenterology 88:1359Google Scholar
  45. Dammann HG, Gottlieb W, Walter T et al. (1986) Nocturnal Acid Suppression with a New H2-Receptor Antagonist — Nizatidine. Hepatogastroenterology 33: 217PubMedGoogle Scholar
  46. Dammann HG, Klotz U, Gottlieb W, Walter T (1986 a) Nizatidine (300 mg nocte) Does Not Interfere with Diazepam Pharmacokinetics. Dig Dis Sei 31 (10 Suppl): Abstract 1570Google Scholar
  47. Dammann HG, Walter T, Müller P, Simon B, Keohane P (1986 b) Nizatidine and Duodenal Ulcer Healing. Dig Dis Sci 31 (10 Suppl): Abstract 948Google Scholar
  48. Dammann HG, Gottlieb W, Walter T, Müller P, Simon B, Keohane P (1987) The 24-Hour Acid Suppression Profile of Nizatidine. Scand J Gastroenterol 22 (Suppl 136): 56Google Scholar
  49. Dammann HG, Dau B, Dreyer M, Müller P, Simon B (1987 a) H2-Rezeptoranta-gonisten in der Therapie der peptischen Ulkuserkrankung. Z Gastroenterol (Suppl 3): 136Google Scholar
  50. Demling L, Domschcke S (1984) Klinische Gastroenterologie, 2. Aufl. Thieme, StuttgartGoogle Scholar
  51. Devis G (1987) Nizatidine in Duodenal Ulcer Disease — European Experience. European Nizatidine Symposium, BrusselsGoogle Scholar
  52. Dicke JM, Johnson RF, Henderson BI, Kühl TJ, Schenker S (1988) A Comparative Evaluation of the Transport of H2-Receptor Antagonists by the Human and Baboon Placenta. Am J Med Sci 295(3): 198PubMedGoogle Scholar
  53. DiMario F (1987) Ranitidine and Nizatidine Action on Peptic Secretion. Gastroenterology 92(5): 1371Google Scholar
  54. Duroux P (1987) Overnight Acid Suppression Profile of Nizatidine 300 mg Effect of 6.00 p.m. and 9.00 p.m. Dosing. European Nizatidine Symposium, BrusselsGoogle Scholar
  55. Dyck W, Cloud M, Offen W, Matsumoto C, Chernish S (1987) Treatment of Duodenal Ulceration in the United States. Scand J Gastroenterol 22 (Suppl 136): 47Google Scholar
  56. Evans D, Ruffolo R, Warrick M, Lin T (1984) Specific Histamine (H-2)-Receptor Antagonist Actions of Nizatidine. Fed Proc 43(4): 1074Google Scholar
  57. Fordtran JS (1985) A Study of the Efficacy of Four Dosis of Nizatidine as Compared to Cimetidine and Placebo as an H2-Antagonist to Suppress Food-stimulated Gastric Acid Secretion in Volunteers. Lilly Research Labs. — Clinical Dokumentation Protocol 20 (unveröffentlichte Daten)Google Scholar
  58. Fullarton GM, McLanchlan G, MacDonald A, Crean GP, McColl KEL (1988) Rebound Noctural Hypersecretion after four Weeks H2-Antagonist therapy. Gut 29: A1439Google Scholar
  59. Ganellin C, Durant G, Emmett J et al. (1985) Recent Structure-Activity Studies of H2-Receptor Histamine Antagonists. Acta Pharm Suec 2 (Suppl): 153Google Scholar
  60. Gledhill T, Howard O, Buch M (1983) Single Nocturnal Dose of an H2-Receptor Antagonist for the Treatment of Duodenal Ulcer. Gut 24: 904PubMedCentralPubMedGoogle Scholar
  61. Grasela T, Welage D, Adelman M (1987) Population Analysis of Nizatidine Concentration — Effect Data. Clin Pharmacol Ther 41 (Suppl 2): 167Google Scholar
  62. Greenblatt DJ, Aberneth D, Morse J (1985) Clinical Importance of the Interaction with Cimetidine. Pharmacol Ther 27: 353Google Scholar
  63. Hagopian GS (1984) A Teratology Study in Dutch Belted Rabbits Given Oral Doses of Nizatidine. Lilly Research Labs. — Toxicology Report Nr.30 (unveröffentlichte Daten)Google Scholar
  64. Hakason R et al. (1986) Gastric and Trophic Control of Gastric Mucosa. Scand J Gastroenterol 21 (Suppl 118): 18Google Scholar
  65. Hammond J, Offen W (1988) Effect of Nizatidine and Cimetidine on Betazole-Stimulated Gastric Secretion of Normal Subjects. Am J Gastroenterol 83(1): 32PubMedGoogle Scholar
  66. Hanlin ML (1981) Anti-Androgenic Studies with Nizatidine in the Male Rat. Lilly Research Labs. — Pharmacology Report Nr.9 (unveröffentlichte Daten)Google Scholar
  67. Hentschel E, Schütze K, Dutch W (1984) Relaps Rates of Duodenal Ulcer Healed with Concentrated Antacid or Cimetidine. Hepatogastroenterology 31: 266PubMedGoogle Scholar
  68. Hentschel E, Schütze K, Reichel W et al. (1987) Nizatidine Versus Ranitidine in the Prevention of Duodenal Ulcer Relapse. Scand J Gastroenterol 22 (Suppl 136): 84Google Scholar
  69. Hill LE (1981) The Effect of Nizatidine on the Induction of DNA Repair Synthesis in Primary Cultures of Adult Rat Hepatocytes. Lilly Research Labs. — Toxicology Report Nr. 14 (unveröffentlichte Daten)Google Scholar
  70. Hirsch KS (1985) Effect of Nizatidine, Cimetidine and Ranitidine of the Tissue Uptake and Nuclear Translocation of 3H-R1181 in the Male Rat. Lilly Research Labs. — Pharmacology Report Nr.12 (unveröffentlichte Daten)Google Scholar
  71. Holland DR, Turk JA, Bemis KG, Beckheim GA (1981) Cardiovascular and Respiratory Effects of Intravenous Administration of Nizatidine in Anesthetized Dogs. Lilly Research Labs. — Pharmacology Report Nr.6 (unveröffentlichte Daten)Google Scholar
  72. Kattau RW, Rathbun RC, Bemis KG (1981) Effects of Nizatidine in Mice. Lilly Research Labs. — Pharmacology Report Nr. 8 (unveröffentlichte Daten)Google Scholar
  73. Kirsch W, Ohnhaus E (1987) Neuere Aspekte zu Arzneimittelwechselwirkungen mit den H2-Antagonisten Cimetidine und Ranitidine. Med Klin 82: 400Google Scholar
  74. Klotz U, Dammann HG, Gottlieb W, Walter T, Keohane P (1987) Nizatidine (300 mg nocte) Does Not Interfere with Diazepam Pharmacokinetics in Man. Br J Clin Pharmacol 23:105PubMedCentralPubMedGoogle Scholar
  75. Klotz U (1987 a) Lack of Effect of Nizatidine on Drug Metabolism. Scand J Gastroenterol 22 (Suppl 136): 18Google Scholar
  76. Klotz U, Gottlieb W, Keohane P, Dammann HG (1987 b) Nocturnal Doses of Ranitidine and Nizatidine Do Not Affect the Disposition of Diazepam. J Clin Pharmacol 27: 210PubMedGoogle Scholar
  77. Klotz U (1987 c) Comparative Effects of H2-Receptor Antagonists on Drug Metabolism in vitro and in vivo. Pharmacol Ther 33:157PubMedGoogle Scholar
  78. Knadler M, Rubin A, Bergstrom R, Callaghan J (1984) Effects of Gelusil, Charcoal and Propantheline on the Bioavailability of the H2-Blocker Nizatidine. Pharmacologist 26: 236Google Scholar
  79. Knadler M, Bergstrom R, Callaghan J, Rubin A (1986) Nizatidine, an H2-Blocker, Its Metabolism and Disposition in Man. Drug Metab Disp 14(2): 175Google Scholar
  80. Knadler M, Bergstrom R, Callaghan J, Obermeyer B, Rubin A (1987) Absorption Studies of the H2-Blocker Nizatidine. Clin Pharmacol Ther 43/5: 514Google Scholar
  81. Koop H, Arnold R (1987) Konsequenzen therapeutischer Langzeitachlorhydrie. Internist 28: 8PubMedGoogle Scholar
  82. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V (1987) The Excitatory Effect of the New Histamin H2-Receptor-Antagonist Nizatidine (LY 390037) on the Guinea Pig lleum. J Pharmacobiodyn 10: 669PubMedGoogle Scholar
  83. Kovacs T, Maxwell V, Sytnik B, Van Deventer G, Walsh J (1986) The Effects of Three Oral Doses of Nizatidine and Placebo on Nocturnal and Peptone-Stimulated Gastric Acid Secretion. Western Sect Gastroenterol 34: 29Google Scholar
  84. Kovacs T, Van Deventer G, Maxwell V, Sytnik B, Walsh J (1986 a) The Effects of an Oral Evening Dose of Nizatidine on Nocturnal and Peptone-Stimulated Gastric Acid Secretion. Gastroenterology 90(5): 1502Google Scholar
  85. Kovacs T, Van Deventer G, Maxwell V, Sytnik B, Walsh J (1987) The Effect of an Oral Evening Dose of Nizatidine on Nocturnal and Peptone-Stimulated Gastric Acid. Scand J Gastroenterol 22 (Suppl 136): 41Google Scholar
  86. Langmann MJS (1985) Antisecretory Drugs and Gastric Cancer. Br Med J 290: 1850Google Scholar
  87. Lanzon-Miller S, Pounder RE, Chronos N, Raymond F, Hamilton MR, Dalgleish D (1988) Twenty-four Hour Intragastric Acidity and Plasma Gastrin Concentration in Healthy Volunteers taking Nizatidine 150 mg, Nizatidine 300 mg, Ranitidine 300 mg, or Placebo at 2100 h. Gut 29:1364PubMedCentralPubMedGoogle Scholar
  88. Lasseier K (1986) Nizatidine Pharmacokinetics in Hepatic Disease. Lilly Research Labs. — Clinical Dokumentation Protocol 37 (unveröffentlichte Daten)Google Scholar
  89. Leslie G, Walter T (1977) A Toxicology Profile of Cimetidine. In: Burland W, Sim-kins M (eds) Cimetidine. Excerpta Medica, Amsterdam, p 24Google Scholar
  90. Levendoglu H, Mehta B, Wait C, Reddy G, Hatcher C (1986) Nizatidine: A New Histamine Receptor Blocker in the Treatment of Active Duodenal Ulcers. Am J Gastroenterol 81(12): 1167PubMedGoogle Scholar
  91. Levendoglu H, Mehta B, Wait C, Reddy G, Hatcher C (1986 a) Effect of Nizatidine on Duodenal Ulcer Healing. IRCS Med Sci 14: 345Google Scholar
  92. Lin T, Evans DC (1981) Gastrointestinal Actions of LY13907. Lilly Research Labs. — Pharmacology Report Nr. 1 (unveröffentlichte Daten)Google Scholar
  93. Lin T (1981 a) Pharmacological Evaluation of Nizatidine in Isolated Smooth and Cardiac Muscle Preparations. Lilly Research Labs. — Pharmacology Report Nr. 5 (unveröffentlichte Daten)Google Scholar
  94. Lin T, Evans D, Warrick M, Pioch R, Ruffolo R (1983) Nizatidine, A New Specific H2-Receptor Antagonist. Gastroenterology 84:1231Google Scholar
  95. Lin T, Evans DC (1984) Effect of Nizatidine on Gastric Acid Secretion Induced by Methacholin HCL. Lilly Research Labs. — Pharmacology Report Nr.3 (unveröffentlichte Daten)Google Scholar
  96. Lin T (1985) Absorption of Nizatidine in Different Segments of the Gastrointestinal Tract. Lilly Research Labs. — Pharmacology Report Nr. 19 (unveröffentlichte Daten)Google Scholar
  97. Lin T, Evans D, Warrick M, Ruffolo R (1986) Actions of Nizatidine on the Rat Uterus, Dog Stomach and Experimentally Induced Gastric Lesions. J Pharmacol Exp Ther 239(2): 400PubMedGoogle Scholar
  98. Lin T, Evans D, Warrick M, Pioch R (1986 a) Actions of Nizatidine, A Selective Histamine H2-Receptor Antagonist, on Gastric Acid Secretion in Dogs, Rats and Frogs. J Pharmacol Exp Ther 239(2): 406PubMedGoogle Scholar
  99. Lindstrom TD, Whitaker G (1985) Effect of Ranitidine, Cimetidine and Nizatidine (LY139037) upon Cytochrome P450 Content in Male Rats and upon Ethylmorphine N-Demethylation in vitro. Lilly Research Labs. — Pharmacology Report Nr.14 (unveröffentlichte Daten)Google Scholar
  100. Lindstrom TD, Whitaker G (1985 a) The Effect of Nizatidine Upon Hepatic Weight, Microsomal Protein and Microsomal Cytochrome P450 in Mice. Lilly Research Labs. — Pharmacology Report Nr.15 (unveröffentlichte Daten)Google Scholar
  101. Linscheer W, Raheja K, Hirose N (1985) A Double Blind Controlled Study Proves Nizatidine to be Much More Potent than Cimetidine. Gastroenterology 88 (5, Part 2): 1478Google Scholar
  102. Lucas RA, Keohane PP (1986) Evaluation of the Pharmaceutics of Nizatidine in Elderly Subjects. Lilly Research Labs. — Clinical Dokumentation Protocol B5Q-17 (unveröffentlichte Daten)Google Scholar
  103. Magee D (1974) Pepsin. Med Clin North Am 58(6): 1277PubMedGoogle Scholar
  104. Meredith C, Speeg K, Schenker S (1983) The Effect of Nizatidine (A New H2-Receptor Antagonist) on Hepatic Oxidative Drug Metabolism in the Rat. Clin Res 31: 765AGoogle Scholar
  105. Meredith C, Speeg K, Schenker S (1985) Nizatidine, A New Histamine H2-Receptor Antagonist, and Hepatic Oxidative Drug Metabolism. Toxicol Appl Pharmacol 77: 315PubMedGoogle Scholar
  106. Miller BJ (1983) A Basic Fertility Study in Wistar Rats given Nizatidine in the Diet. Lilly Research Labs. — Toxicology Report Nr. 25 (unveröffentlichte Daten)Google Scholar
  107. Miller BJ (1983 a) A Basic Fertility Study in Fischer 344 Rats Given Nizatidine in the Diet. Lilly Research Labs. — Toxicology Report Nr.24 (unveröffentlichte Daten)Google Scholar
  108. Miller BJ (1985) A Fertility, Perinatal and Postnatal Study in Wistar Rats given Diets on Containing Nizatidine. Lilly Research Labs. — Toxicology Report Nr. 39 (unveröffentlichte Daten)Google Scholar
  109. Miller L (1987) 24-hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking Nizatidine 150, 300, Ranitidine 300 oder placebo at 21.15. Gastroenterology 92 (5, Part 2): 1492Google Scholar
  110. Missale G, Agosti A, Bertele A (1987) Inhibition of gastric acid secretion in man by nizatidine and ranitidine. Ital J Gastroenterol 19(5): 261Google Scholar
  111. Mitchell M (1987) Nizatidine Maintenance Therapy in Duodenal Ulcer Disease-European Experience. European Nizatidine Symposium, BrusselsGoogle Scholar
  112. Morton D (1987) Pharmacology and Toxicology of Nizatidine. Scand J Gastroenterol 22 (Suppl 136): 1Google Scholar
  113. Müller P, Dammann HG, Simon B (1985) Gezielte Hemmung der nächtlichen Säuresekretion. MMW 127(43): 1019Google Scholar
  114. Naccaratto R, Cremer M, Dammann HG et al. (1987) Nizatidine Versus Raniti-dine in Gastric Ulcer Disease. Scand J Gastroenterol 22 (Suppl 136): 71Google Scholar
  115. Neal SG (1982) The Effect of LY139037 on the In Vivo Induction of Sister Chromatic Exchange in Bone Marrow of Chinese Hamsters. Lilly Research Labs. — Toxicology Report Nr.20 (unveröffentlichte Daten)Google Scholar
  116. Neal SG (1982 a) The Effect of Nizatidine in the In Vivo Induction of Sister Chromatid Exchange in Bone Marrow of Chinese Hamsters. Lilly Research Labs. — Toxicology Report Nr.21 (unveröffentlichte Daten)Google Scholar
  117. Neubauer BL (1984) Endocrine Studies with Nizatidine, Cimetidine and Ranitidine HC1 in the Male Rat. Lilly Research Labs. — Pharmacology Report Nr.11 (unveröffentlichte Daten)Google Scholar
  118. Newman KS (1981) A Subchronic Toxicity Study of Nizatidine Given in Daily Intraveneous Doses to Fischer 344 Rats for 1 Month. Lilly Research Labs. — Toxicology Report Nr.9 (unveröffentlichte Daten)Google Scholar
  119. Newman KS (1981 a) The Acute Intravenous Toxicity of Nizatidine in Dogs. Lilly Research Labs. — Toxicology Report Nr. 5 (unveröffentlichte Daten)Google Scholar
  120. Newman KS (1981 b) The Acute Intramuscular Toxicity of Nizatidine in Dogs. Lilly Research Labs. — Toxicology Report Nr.7 (unveröffentlichte Daten)Google Scholar
  121. Newman KS (1981 c) The Acute Intraveneous Toxicity of Nizatidine in Monkeys. Lilly Research Labs. — Toxicology Report Nr.6 (unveröffentlichte Daten)Google Scholar
  122. Newman KS (1981 d) The Subchronic Toxicity of Nizatidine Given in Daily Intravenous Doses to Dogs for 1 Month. Lilly Research Labs. — Toxicology Report Nr.11 (unveröffentlichte Daten)Google Scholar
  123. Newman KS (1983) A Subchronic Toxicity Study of Nizatidine Given in the Diet to Fischer 344 Rats for 3 Months. Lilly Research Labs. — Toxicology Report Nr.22 (unveröffentlichte Daten)Google Scholar
  124. Newman KS (1983 a) A Subchronic Toxicity Study of Nizatidine in Beagle Dogs Receiving Daily Oral Doses of Nizatidine for Three Months. Lilly Research Labs. — Toxicology Report Nr.23 (unveröffentlichte Daten)Google Scholar
  125. Newman KS (1983 b) A Comparison of Nizatidine with Cimetidine for Inhibition of Aromatose Activity. Lilly Research Labs. — Toxicology Report Nr.28 (unveröffentlichte Daten)Google Scholar
  126. Offen W, Matsumoto C, Cloud M (1986) Efficacy of 8 Weeks of Nizatidine Therapy in the Treatment of Acute Duodenal Ulcer. Am J Gastroenterol 81(9): 867Google Scholar
  127. Offen W, Matsumoto C, Cloud M (1986 a) The Effectiveness of 4 to 8 Weeks of Nizatidine 150 mg Twice Daily in the Treatment of Active Duodenal Ulcer Disease. Am J Gastroenterol 81(9): 867Google Scholar
  128. Pace F, Colombo E, Ferrara A, Prada A, Rocca F, Bianchi Porro G (1988) Treatment of Duodenal Ulcer. A Cooperative Double-Blind Study of Once-DailyBedtime Administration. Am J Gastroenterol 83(6): 643PubMedGoogle Scholar
  129. Pasanen M, Arvela P, Pelkonen O, Sotaniemi E, Klotz U (1986) Effect of 5 Structurally Diverse H2-Receptor Antagonists on Drug Metabolism. Biochem Pharmacol 35(34): 4457PubMedGoogle Scholar
  130. Penston J, Wormsley KG (1987) Achlorhydria: Hypergastrinaemia: Carcinoids — a Flawed Hypothesis? Gut 28: 488PubMedCentralPubMedGoogle Scholar
  131. Pippenger CE (1982) Drug Protein Binding. An Overview. In: Moyer T, Boeckx R (eds) Applied Therapeutic Drug Monitoring Fundamentals, Vol 1. Am Ass for Clinical Chemistry, Washington DC, p 55Google Scholar
  132. Porro GB (1985) Efficacy and Safety of Acid Suppression by Oral Nizatidine in Volunteer Subjects. Lilly Research Labs. — Clinical Dokumentation Protocol B5Q-13 (unveröffentlichte Daten)Google Scholar
  133. Porro GB (1987) Nizatidine in the Treatment of Gastric Ulcer Disease. European Nizatidine Symposium, BrusselsGoogle Scholar
  134. Poynter D et al. (1981) The Clinical Use of Ranitidine. Proc. 2. Int Symp on Ranitidine, Medicine Publishing Foundation, OxfordGoogle Scholar
  135. Probst KS (1984) A Subchronic Toxicity Study of Nizatidine Given in the Diet to B6C3F1 Mice for 3 Months. Lilly Research Labs. — Toxicology Report Nr.36 (unveröffentlichte Daten)Google Scholar
  136. Probst KS (1984 a) A Chronic Toxicity Study of Nizatidine Given in the Diet to Fischer 344 Rats for Six Months. Lilly Research Labs. — Toxicology Report Nr.34 (unveröffentlichte Daten)Google Scholar
  137. Probst KS (1985) Placental Transfer and Milk Excretion of Radiocarbon Following the Administration of a Single Oral Dose of 14C Nizatidine to Fendle Rats. Lilly Research Labs. — Toxicology Report Nr.40 (unveröffentlichte Daten)Google Scholar
  138. Probst KS, Bernhard NR (1985 a) A Chronic Toxicity Study in Beagle Dogs Given Daily Oral Doses of Nizatidine for One Year. Lilly Research Labs. — Toxicology Report Nr.38 (unveröffentlichte Daten)Google Scholar
  139. Probst KS (1985 b) A Chronic Toxicity Study of Nizatidine Given in the Diet to Fischer 344 Rats for One Year. Lilly Research Labs. — Toxicology Report Nr.37 (unveröffentlichte Daten)Google Scholar
  140. Probst KS (1985 c) A Chronic Toxicity/Oncogenicity Study of Nizatidine Given in the Diet to B6C3F1 Mice for Two Years. Lilly Research Labs. — Toxicology Report Nr.41 (unveröffentlichte Daten)Google Scholar
  141. Probst KS (1986) The Effects of Nizatidine (LY139037) on the Hepatic Microsomal Enzyme Activity. Lilly Research Labs. — Toxicology Report Nr.47 (unveröffentlichte Daten)Google Scholar
  142. Probst KS (1986 a) A Chronic Toxicity/Oncogenicity Study in Fischer 344 Rats Given Nizatidine in the Diet for Two Years. Lilly Research Labs. — Toxicology Report Nr.46 (unveröffentlichte Daten)Google Scholar
  143. Probst KS (1986 b) The Effect of Nizatidine on the Induction of Chromosome Aberrations in Cultured CHO Cells. Lilly Research Labs. — Toxicology Report Nr. 52 (unveröffentlichte Daten)Google Scholar
  144. Quarles JP (1981) The Acute Subcutaneous Toxicity of Nizatidine in ICR Mice. Lilly Research Labs. — Toxicology Report Nr.15 (unveröffentlichte Daten)Google Scholar
  145. Quarles JP (1981 a) The Acute Subcutaneous Toxicity of Nizatidine in Fischer 344 Rats. Lilly Research Labs. — Toxicology Report Nr.16 (unveröffentlichte Daten)Google Scholar
  146. Rainen D, Curik M, Rodvold K, Deyo K, Scaros L, Fischer J (1988) Stability of Nizatidine in Commonly used Intraveneous Fluids and Containers. Am J Hosp Pharmacol 45:1523Google Scholar
  147. Reichel W, Brandstätter G, Hentschel E et al. (1987) Nizatidine vs. Ranitidine in der Therapie des Ulcus duodeni. Z Gastroenterol 25(8): 545Google Scholar
  148. Rexroat MA (1984) The Effect of Nizatidine on the Induction of Reverse Mutations in Salmonella typhimurium Using the Ames Test. Lilly Research Labs. — Toxicology Report Nr. 32 (unveröffentlichte Daten)Google Scholar
  149. Roberts NB, Sheers R, Taylor W (1981) Pepsin 1 Secretion in Normal Human Subjects. Clin Sci 61: 37Google Scholar
  150. Roberts CJC (1984) Clinical Pharmacokinetics of Ranitidine. Clin Pharmakokinet 9:211Google Scholar
  151. Roberts R, Heath C, Johnson R, Speeg K, Schenker S (1986) Effect of H2-receptor Antagonists on Steady-State Extraction of Indocyanine Green and Lidocaine. J Lab Clin Med 107(2): 112PubMedGoogle Scholar
  152. Ryan J (1985) The Effect of Three Oral Doses of Nizatidine and Placebo on Nocturnal and Food stimulated Gastric Acid Secretion. Lilly Research Labs. — Clinical Dokumentation Protocol 32 (unveröffentlichte Daten)Google Scholar
  153. Ryan J, Vargas R, McMahon F, Gotzkowsky S, Matsumoto C (1986) Dose-Response Efficacy of Intraveneous Nizatidine on Gastric Secretion and Acidity. Am J Gastroenterol 81(9): 857Google Scholar
  154. Samanta A, Nahass D, Habba S (1986) Efficacy of Nizatidine: A New H2-Receptor Antagonist in the Treatment of Duodenal Ulcer: A Dose Response Study. Am J Gastroenterol 81(9): 852Google Scholar
  155. Schenker S, Johnson R, Mor L, Henderson G, Dicke J (1986) Human Placental Transport of Cimetidine, Ranitidine and Nizatidine. Clin Res 34(2): 445AGoogle Scholar
  156. Secor J, Speeg K Meredith C, Johnson R, Snowdy P, Schenker S (1985) Lack of Effect of Nizatidine on Hepatic Drug Metabolism in Man. Br J Clin Pharmacol 20: 710PubMedCentralPubMedGoogle Scholar
  157. Sever P (1984) Efficacy and Safety of Acid Suppression by Oral Nizatidine LY 139037 in Volunteer Subjects. Lilly Research Labs. — Clinical Dokumentation Protocol 31 (unveröffentlichte Daten)Google Scholar
  158. Shaar CJ (1982) Effect of Nizatidine and Cimetidine on Plasma Prolactin Concentration in Male Rats. Lilly Research Labs. — Pharmacology Report Nr.10 (unveröffentlichte Daten)Google Scholar
  159. Simon B (1986) Beschleunigte Ulkus Duodeni-Abheilung unter 300 mg Nizatidine nocte. Z Gastroenterologie 24(9): 465Google Scholar
  160. Simon B (1986 a) Nocturnal Nizatidine Accelerates Duodenal Ulcer Healing. Dig Dis Sci 31,10 (Suppl): Abstract 1926Google Scholar
  161. Simon B, Cremer M, Dammann HG et al. (1987) 300 mg Nizatidine at Night Versus 300 mg Ranitidine at Night in Patients with Duodenal Ulcer. Scand J Gastroenterol 22 (Suppl 136): 61Google Scholar
  162. Soll AN (1978) The Action of Secretagogues on Oxygen Uptake by Isolated Mammalian Parietal Cells. J Clin Invest 61: 371Google Scholar
  163. Somogyi A (1983) Clinical Pharmacokinetics of Cimetidine. Clin Pharmacokinet 8:463PubMedGoogle Scholar
  164. Spahn H (1989) Lack of Significant Effect of Nizatidine and Ranitidine on the Plasma Concentrations of Metoprolol Enatiomers. Submitted: Br J Clin PharmacolGoogle Scholar
  165. Streett CS et al. (1984) Pathologic Findings in the Stomachs of Rats Treated with the H2-Receptor Antagonist Tiotidine. Scand J Gastroenterol 19 (Suppl 101): 109Google Scholar
  166. Stone RL (1981) Test of Compound Nizatidine for Effects of the Immune Response in Mice. Lilly Research Labs. — Pharmacology Report Nr.13 (unveröffentlichte Daten)Google Scholar
  167. Sullivan HR (1981) Preclinical Pharmakokinetics and Metabolism Studies. Lilly Research Labs. — Pharmacology Report Nr.15 (unveröffentlichte Daten)Google Scholar
  168. Sullivan HR (1982) Preclinical Pharmacokinetics and Metabolism Studies. Lilly Research Labs. — Pharmacology Report Nr. 16 (unveröffentlichte Daten)Google Scholar
  169. Sullivan HR (1984) Preclinical Pharmacokinetics and Metabolism Studies. Lilly Research Labs. — Pharmacology Report Nr.17 (unveröffentlichte Daten)Google Scholar
  170. Sundler F et al. (1986) Inhibition of Gastric Acid Secretion by Omeprazole and Ranitidine. Scand J Gastroenterol 21 (Suppl 118): 38Google Scholar
  171. Thiel van D, Gavaler J, Heyl A, Susen B (1987) An Evaluation of the AntiAndrogen Effects Associated with H2-Antagonist Therapy. Scand J Gastroenterol 22 (Suppl 136): 24Google Scholar
  172. Thompson CZ (1980) The Effect of Nizatidine on the Induction of Bacterial Mutation Using a Modification of the Ames Test. Lilly Research Labs. — Toxicology Report Nr.13 (unveröffentlichte Daten)Google Scholar
  173. Turner JC, Sullivan HR (1986) Nizatidine Preclinical Pharmacokinetics and Metabolic Transformation Studies. Lilly Research Labs. — Pharmacology Report Nr.20 (unveröffentlichte Daten)Google Scholar
  174. Vargas R, Ryan J, McMahon F, Regel C (1985) The Comparative Efficacy of Nizatidine to Cimetidine in Gastric Hypersecretors. J Clin Pharmacol 25(6): 455Google Scholar
  175. Vargas R, Ryan J, McMahon G, Regel C, Offen W, Matsumoto C (1988) Pharmacokinetics and Pharmacodynamics of Oral Nizatidine. J Clin Pharmacol 28: 71PubMedGoogle Scholar
  176. Venables C (1986) Mucus, Pepsin, and Peptic Ulcer. Gut 27: 233PubMedCentralPubMedGoogle Scholar
  177. Warrick MW, Lin TM (1976) Actions of Somatostatine and Metiamide on Gastric Acid Secretion from Isolated Bullfrog Gastric Mucosa. Res Commun Chem Pathol Pharmacol 13:149PubMedGoogle Scholar
  178. Welage L, Wing P, Thomas R, Mueller G, Bernhard H, Schentag J (1986) The Effect of Intraveneous Nizatidine on Stimulated Gastric Acid Secretion. J Clin Pharmacol 26: 559Google Scholar
  179. Welage L, Grasela T, Thomas R, Wing P, Mueller G (1987) The Concentration Effect Relationship of Nizatidine on Stimulated Gastric Acid Secretion. Clin Pharmacol Ther 41(2): 225Google Scholar
  180. White JF (1981) A 14-Day Acute Toxicity Study of LY139037 Administered Orally to Beagle Dogs. Lilly Research Labs. — Toxicology Report Nr.17 (unveröffentlichte Daten)Google Scholar
  181. Winters SJ, Banks JL, Loriaux DL (1979) Cimetidine is an Anti-Androgen in the Rat. Gastroenterology 76: 504PubMedGoogle Scholar
  182. Wormsley KG (1982) Ranitidin in der Rezidivprophylaxe der peptischen Ulkuserkrankung. Gastroenterolog Prax Suppl II: 19Google Scholar
  183. You C, Lee S, Chey W (1985) The Effect of New H2-Blocker (Nizatidine) on Gastric Acid Secretion: Comparison with Cimetidine. Gastroenterology 88:1639Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • Rudolf Arnold
    • 1
  • Hanns-Gerd Dammann
    • 2
  • Peter Minartz
    • 3
  • Hans-Dieter Peters
    • 4
  • Bernd Simon
    • 5
  1. 1.Zentrum Innere Medizin, Abteilung für GastroentrologieKlinikum der Philipps-UniversitätMarburg/LahnDeutschland
  2. 2.Krankenhaus BethanienHamburg 20Deutschland
  3. 3.Schwerpunktkrankenhaus ElmshornElmshornDeutschland
  4. 4.Bonn-Kessenich 1Deutschland
  5. 5.Krankenhaus SchwetzingenSchwetzingenDeutschland

Personalised recommendations